NATERA, INC. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Natera sequences DNA and RadNet reads scans, and economically they are landlord and laboratory in reverse: Natera's losses (negative 9.1% net) are chosen, growth spending on a screening franchise, while RadNet's (negative 0.7%) are the structural squeeze of imaging-center economics under 0.82 turns of debt. The market prices intent at seven times accident: $37B against $5B. RadNet generates real cash anyway, a 7.2% free-cash yield out of depreciation accounting; Natera returns almost nothing while it builds. Neither carries a usable multiple. The pair shows the diagnostics premium at its purest: molecular futures are priced on ambition, physical infrastructure on evidence, and the gap is enormous.
Comparison updated 2026-07-10.
| Metric | NTRA | RDNT |
|---|---|---|
| Price | $260.64 | $60.71 |
| Market cap | $36.9B | $4.7B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | 20.79 | 3.46 |
| P/S | 14.75 | 2.18 |
| EV/EBITDA | — | 23.8 |
| Revenue growth | +36.4% | +14.7% |
| Operating margin | -13.4% | -4.2% |
| Net margin | -9.1% | -0.7% |
| Return on equity | -12.8% | -1.1% |
| Return on assets | -8.7% | -0.4% |
| Return on invested capital | -13.8% | 2.0% |
| FCF yield | 0.3% | 7.2% |
| Debt / equity | 0.05 | 0.82 |
| Current ratio | 2.96 | 1.17 |
| Altman Z (solvency) | 5.81 | 1.63 |
| Piotroski F (quality) | 4 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.